Holen Sie sich die Stockscreener-App
17.48
1.19%
-0.21
Handel nachbörslich:
17.48
Schlusskurs vom Vortag:
$17.69
Offen:
$18.1
24-Stunden-Volumen:
567.80K
Relative Volume:
0.74
Marktkapitalisierung:
$2.26B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.40%
1M Leistung:
-16.08%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.17
$18.27
1-Wochen-Bereich:
$16.76
$18.76
52-Wochen-Spanne:
$16.76
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Firmenname
Kailera Therapeutics Inc
Sektor
Branche
Telefon
508-440-9475
Adresse
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
17.48 | 2.29B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-12 | Eingeleitet | Evercore ISI | Outperform |
| 2026-05-12 | Eingeleitet | JP Morgan | Overweight |
| 2026-05-12 | Eingeleitet | Jefferies | Buy |
| 2026-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2026-05-12 | Eingeleitet | TD Cowen | Buy |
| 2026-05-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Patent fight erupts around next generation of multibillion-dollar GLP-1 weight-loss drugs - The Business Journals
Yuting Liu Net Worth (2026) - GuruFocus
Jamie Beth Coleman Net Worth (2026) - GuruFocus
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Net Worth (2026) - GuruFocus
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Scott M. Wasserman Net Worth (2026) - GuruFocus
Stuart Partners, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowWhat's Next? - MarketBeat
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential - Yahoo Finance
Kailera's obesity drug meets main goal of late-stage trials in China - MSN
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win - Seeking Alpha
5 Best IPO Stocks with Huge Upside Potential - Insider Monkey
Kailera Therapeutics (KLRA) officer receives 175,000 stock options at $23.30 strike - Stock Titan
Kailera Therapeutics (KLRA) officer Kathleen Tregoning files initial Form 3 - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Kailera weight loss pill trial results: Nausea sinks stock - qz.com
Europe will accelerate its review of RevMed’s drug - STAT
Kailera reports positive Phase III data for oral GLP-1 obesity candidate - The Pharma Letter
Kailera shares tumble on high nausea rates despite weight-loss drug's success | Business Information & News | FE - Westlaw Today
Kailera Therapeutics (KLRA) Company presentation Summary - Quartr
Kailera Therapeutics (KLRA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Kailera Therapeutics (KLRA) Registration filing Summary - Quartr
Kailera falls after late-stage trial data for oral GLP-1 candidate - MSN
Kailera/Hengrui’s Oral GLP-1 Looks Effective, But GI Toxicity Raises Concern - insights.citeline.com
Kailera shares tumble on high nausea rates despite weight-loss drug's success - MSN
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall - Moomoo
Kailera shares tumble on high nausea rates despite weight-loss drug’s success - Y100 WNCY
The stock price of Kailera Therapeutics, Inc. (KLRA) rose by 1.9% in pre-market trading. - Bitget
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily
Kailera reports 11.1% weight loss data - grafa.com
Kailera says obesity pill succeeds in late-stage trial in China - BioPharma Dive
Kailera posts late-stage trial data for oral GLP-1 drug (KLRA) - Seeking Alpha
Kailera Therapeutics Announces Positive Topline Data From Two Hengrui Pharma Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 - marketscreener.com
Kailera’s obesity drug meets main goal of late-stage trials in China - 101 WIXX
Kailera’s weight-loss drug meets main goal of late-stage trials in China - hi99.com
Kailera's weight-loss drug meets main goal of late-stage trials in China - marketscreener.com
Kailera's GLP-1 drug meets main goal of late-stage trials - Yahoo Finance
Kailera Therapeutics Announces Positive Topline Data from - GlobeNewswire
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - Yahoo Finance
Kailera appoints Kathleen Tregoning as chief corporate affairs officer - The Pharma Letter
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Value Benchmark - marketscreener.com
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - The Manila Times
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Finanzdaten der Kailera Therapeutics Inc-Aktie (KLRA)
Es liegen keine Finanzdaten für Kailera Therapeutics Inc (KLRA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):